Assessing therapeutic decisions in generalized myasthenia gravis: Study protocol
The study findings will contribute to better understanding of decision-making in gMG under a changing therapeutic landscape with multiple new targeted options, and will identify which factors have a role in affecting those decisions.
Authors
- Gerardo Gutiérrez‐Gutiérrez (ORCID: https://orcid.org/0000-0003-1391-754X)
- Paola Díaz-Abós (ORCID: https://orcid.org/0000-0002-7097-0665)
- Ignacio Escobar (ORCID: https://orcid.org/0000-0002-1068-0455)
- Luís Querol (ORCID: https://orcid.org/0000-0002-4289-8264)
- M. Sarmiento
- Rocío Gómez-Ballesteros (ORCID: https://orcid.org/0000-0001-9582-9230)
- Pablo Rebollo (ORCID: https://orcid.org/0000-0002-7517-6540)
- Ramón Villaverde (ORCID: https://orcid.org/0000-0002-0064-8910)
- Ana Núñez Ares
- Virginia Reyes
- Thaís Armangué (ORCID: https://orcid.org/0000-0001-6192-6171)
- Javier Sotoca (ORCID: https://orcid.org/0000-0003-3400-1434)
- Jorge Mauriño (ORCID: https://orcid.org/0000-0001-9858-3555)
- Elisa Salas
Institutions
- Hospital Sant Joan de Déu Barcelona (ES)
- Hospital de Sant Pau (ES)
- IQVIA (United Kingdom) (GB)
- Hospital General Universitario Morales Meseguer (ES)
- Hospital Regional Universitario de Málaga (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Roche (Spain) (ES)
- Hospital Universitario Infanta Sofía (ES)
- Complejo Asistencial Universitario de Palencia (ES)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1371/journal.pone.0322168
- Citations
- 2
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Eli Lilly and Company
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- CSL Behring
- Argenx
- Roche España
- Grifols
- UCB Pharma